Bassel El-Rayes, MD

Articles by Bassel El-Rayes, MD

Translating Real-World Outcomes in mCRC Into Patient Conversations

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 29th 2025

Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line metastatic colorectal cancer therapies.

Leveraging Real-World Evidence in Sequencing Decisions for mCRC

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 29th 2025

Panelists discuss how RWE helps guide sequencing choices when head-to-head trial data are lacking in third-line metastatic colorectal cancer.

Selecting Among Third-Line Therapies in Clinical Practice for mCRC

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 22nd 2025

Panelists discuss how efficacy, safety, quality of life, and patient-specific factors drive selection among third-line therapies in metastatic colorectal cancer.

Efficacy of Fruquintinib and Comparisons Across Agents in mCRC

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 22nd 2025

Panelists discuss how data from FRESCO-2 and other trials position fruquintinib as a strong third-line option compared with regorafenib and FTD/TPI.

Evidence Supporting FTD/TPI ± Bevacizumab in mCRC

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 15th 2025

Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.

Overview of Available Third-Line Options in mCRC

ByRyan Haumschild, PharmD, MS, MBA,Patrick Boland, MD,Fadi Braiteh, MD,Christine Parseghian, MD,Bassel El-Rayes, MD

October 15th 2025

Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.

Bassel El-Rayes, MD

Articles by Bassel El-Rayes, MD

Translating Real-World Outcomes in mCRC Into Patient Conversations

Leveraging Real-World Evidence in Sequencing Decisions for mCRC

Selecting Among Third-Line Therapies in Clinical Practice for mCRC

Efficacy of Fruquintinib and Comparisons Across Agents in mCRC

Evidence Supporting FTD/TPI ± Bevacizumab in mCRC

Overview of Available Third-Line Options in mCRC

Latest Updated Articles

Trending on AJMC

Changing Tumor Classifications May Explain Rise in Early-Onset CRC

Medicaid Work Requirements Set to Leave Millions Without Insurance

Remote Physiological Monitoring Improves Patient Access, Care, and Revenue

COVID-19 Vaccination Linked to Lower Risk of Long COVID in Adolescents

Choosing the Right Site of Care Could Cut Outpatient Surgery Costs in Half: Xiaoxi Zhao, PhD